Ultragenyx Pharmaceutical Inc. (RARE) Business Metric Overview - Stocknear

Ultragenyx Pharmaceutical...

NASDAQ: RARE · Real-Time Price · USD
31.82
0.54 (1.73%)
At close: Sep 05, 2025, 3:59 PM
31.82
0.00%
After-hours: Sep 05, 2025, 05:10 PM EDT

Ultragenyx Pharmaceutical Revenue Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Product Revenue 80.82M 91.51M 71.87M 77.25M 73.81M 62.49M 138.06M 42.35M
Product Revenue Growth -11.68% +27.32% -6.97% +4.67% +18.11% -54.74% +226.01% n/a
Royalty Revenue 85.68M 47.78M 93.01M 62.24M 73.22M 46.34M 126.95M 55.7M
Royalty Revenue Growth +79.30% -48.62% +49.43% -14.99% +57.99% -63.49% +127.90% n/a

Revenue by Geography

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Asia Pacific Revenue 4.2M 3.29M 3.57M 2.31M 3.05M 35.18M 18.25M 17.23M 19.07M 22.8M 8.26M 14.12M 12.54M 9.79M 70.89M 66.91M 75.57M 87.74M 82.73M 72.65M
Asia Pacific Revenue Growth +27.85% -7.96% +54.50% -24.29% -91.33% +92.80% +5.90% -9.64% -16.36% +175.95% -41.48% +12.60% +28.07% -86.19% +5.95% -11.45% -13.88% +6.06% +13.87% n/a
Emea Revenue 26.4M 54.89M 18.56M 38.05M 38.93M 57.68M 92.92M 67.81M 79.29M 67.13M 84.83M 67.01M 67.33M 61.92M n/a n/a n/a n/a n/a n/a
Emea Revenue Growth -51.90% +195.76% -51.22% -2.26% -32.51% -37.92% +37.02% -14.48% +18.11% -20.86% +26.59% -0.47% +8.74% n/a n/a n/a n/a n/a n/a n/a
Latin America Revenue 32.97M 57.79M 116.98M 76.91M 88.89M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Latin America Revenue Growth -42.96% -50.60% +52.09% -13.47% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
North America Revenue 102.93M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
North America Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Operating Expense Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 86.65M 87.8M 82.5M 80.35M 80.6M 78.16M 76.83M 74.92M 81.4M 76.65M 72.85M 69.84M 68.14M 67.31M 59.43M 53.88M 53.41M 53.26M 51.04M 42.12M 42.25M 47.52M 41.88M 41.01M 39.81M 38.83M 34.48M 31.09M 30.72M 31.43M 37.72M 23.5M 20M 18.68M 19.81M 17.18M 14.74M 13.21M 11.59M 10.23M 7.04M 4.14M
Selling, General, and Administrative Revenue Growth -1.31% +6.43% +2.67% -0.31% +3.13% +1.73% +2.56% -7.97% +6.21% +5.21% +4.31% +2.50% +1.23% +13.26% +10.30% +0.89% +0.29% +4.34% +21.17% -0.31% -11.08% +13.47% +2.12% +3.00% +2.53% +12.63% +10.87% +1.23% -2.28% -16.66% +60.52% +17.47% +7.06% -5.67% +15.28% +16.59% +11.59% +13.92% +13.30% +45.38% +70.08% n/a
Research and Development Revenue 156.12M 165.77M 187.77M 170.11M 152.64M 169.64M 160.56M 157.25M 164.95M 165.7M 170.81M 237.3M 154.53M 143.16M 123.01M 113.42M 113.2M 147.52M 131.1M 87.31M 80.71M 112.96M 83.06M 100.14M 96.05M 78.11M 71.62M 70.04M 76.83M 75.5M 61.53M 60.41M 58.44M 51.27M 50.75M 48.71M 43.33M 40.41M 44.56M 29.7M 23.1M 17.36M
Research and Development Revenue Growth -5.82% -11.71% +10.38% +11.44% -10.02% +5.66% +2.11% -4.67% -0.45% -2.99% -28.02% +53.56% +7.95% +16.37% +8.46% +0.19% -23.26% +12.52% +50.15% +8.18% -28.55% +36.00% -17.06% +4.27% +22.97% +9.06% +2.25% -8.84% +1.76% +22.72% +1.85% +3.38% +13.98% +1.03% +4.18% +12.41% +7.22% -9.31% +50.03% +28.57% +33.06% n/a